Skip to main content
LXRX
NASDAQ Life Sciences

Lexicon Q3 10-Q: $183.2M Cash, Wider $46.8M Nine-Month Loss, Hercules Debt in Place

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.613
Mkt Cap
$716.379M
52W Low
$1.1
52W High
$2.68
52W Position info
47% above low
Off High info
40% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

LXRX sits 47% above its 52-week low of $1.1.

Summary

Lexicon's Q3 10-Q shows $183.2 million in cash and investments against a $46.8 million nine-month net loss, with the new Hercules term loan carrying a minimum cash covenant starting June 1, 2027.


Key Events · Earnings and Guidance · LXRX

  • Q3 Revenue Falls on Smaller Milestone

    Total revenue was $11.3 million versus $14.2 million a year ago; $10.0 million came from the Novo Nordisk license milestone and only $1.2 million from INPEFA product sales.

  • Cash Position Rises to $183.2M

    Cash, cash equivalents and short-term investments reached $183.2 million at September 30, 2026, up from $125.2 million at December 31, 2025, after $96.2 million of net February equity proceeds.

  • Nine-Month Net Loss Widens

    Net loss was $46.8 million, or $0.11 per share, versus $34.8 million, or $0.10 per share, a year earlier, including a $4.3 million loss on early extinguishment of the Oxford debt.

  • Hercules Loan Covenant Starts June 2027

    The $100 million Hercules facility had $55 million funded at a 10.10% rate; a minimum cash covenant begins June 1, 2027, extendable to January 1, 2028 on milestone achievement and waivable at specified market caps.


Analysis · LXRX · Life Sciences

The headline numbers were already out this morning, but the 10-Q is where the balance sheet lives: $183.2 million of cash and short-term investments at September 30 versus $125.2 million at year-end, after a February raise that netted $96.2 million and a May refinancing that swapped the Oxford loans for a $100 million Hercules facility. That cash covers the stated 12-month runway, but the nine-month net loss widened to $46.8 million from $34.8 million, and the Hercules minimum cash covenant begins June 1, 2027 — the date that matters if the SONATA-HCM readout or a ZYNQUISTA resubmission slips. Revenue of $11.3 million was almost entirely the $10 million Novo Nordisk milestone, so product sales of $1.2 million remain the weak spot.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LXRX was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $716.4M. The 52-week trading range was $1.10 to $2.68. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LXRX - Latest Insights

LXRX
Nov 05, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.50 info
Change: -$0.1075 (-7%) info
Market Cap: $681.209M info
LXRX
Nov 05, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $1.50 info
Change: -$0.1075 (-7%) info
Market Cap: $681.209M info
LXRX
Aug 31, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.30
Real-time Price: $1.50 info
Change: -$0.7975 (-35%) info
Market Cap: $681.209M info
LXRX
Aug 24, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.38
Real-time Price: $1.50 info
Change: -$0.8775 (-37%) info
Market Cap: $681.209M info
LXRX
Aug 06, 2026, 7:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.95
Real-time Price: $1.50 info
Change: -$0.4475 (-23%) info
Market Cap: $681.209M info